Credit Suisse Upgrades Thoratec To Outperform

Analysts at Credit Suisse upgraded Thoratec

from Neutral to Outperform. The price target for Thoratec has been raised from $27.00 to $35.00. Thoratec shares have dropped 30.46% over the past 52 weeks, while the S&P 500 index has surged 14.18% in the same period. Thoratec's shares fell 2.01%to close at $29.20 yesterday.